azomycin has been researched along with amifostine anhydrous in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kligerman, MM; Peterson, DF; West, G; Yuhas, JM; Yurconic, M | 1 |
| Chapman, JD; Urtasun, RC | 1 |
| Conger, AD; Pratt, NE; Sinesi, M; Sodicoff, M; Trepper, P | 1 |
| Chapman, JD; Kanclerz, A | 1 |
| Brown, JM | 1 |
| Phillips, TL | 1 |
| Twentyman, PR | 1 |
| Chu, FC; Kim, JH | 1 |
| Grigsby, P; Maruyama, Y | 1 |
| Denekamp, J; Rojas, A; Stewart, FA | 2 |
| McNally, NJ | 1 |
| Hunter, N; Ito, H; Milas, L | 1 |
| Beach, JL; Grigsby, PW; Mendiondo, OA | 1 |
| Begg, AC; Terry, NH | 1 |
| Denekamp, J; Rojas, A | 1 |
| Tsukiyama, I | 1 |
| Denekamp, J; Williams, MV | 1 |
3 review(s) available for azomycin and amifostine anhydrous
| Article | Year |
|---|---|
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione; Humans; Misonidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiotherapy | 1985 |
Sensitizers and protectors in clinical oncology.
Topics: Alkylating Agents; Amifostine; Animals; Drug Synergism; Humans; Mice; Misonidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Organothiophosphorus Compounds; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1981 |
Chemical radiation sensitizers and protectors: recent developments.
Topics: Amifostine; Cysteamine; Cysteine; DNA, Neoplasm; Humans; Neoplasms; Nitroimidazoles; Nucleic Acid Conformation; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents; Sulfhydryl Compounds | 1981 |
1 trial(s) available for azomycin and amifostine anhydrous
| Article | Year |
|---|---|
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione; Humans; Misonidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiotherapy | 1985 |
15 other study(ies) available for azomycin and amifostine anhydrous
| Article | Year |
|---|---|
Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy.
Topics: Amifostine; Animals; Cell Line; Cell Survival; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Nitroimidazoles; Organothiophosphorus Compounds; Radiation-Protective Agents; Radiation-Sensitizing Agents; Time Factors | 1977 |
The application in radiation therapy of substances which modify cellular radiation response.
Topics: Amifostine; Animals; Drug Evaluation; Drug Therapy, Combination; Humans; Metronidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen Consumption; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1977 |
Chemoradioprotection of the rat parotid gland by combined use of WR-2721 and Ro-07-0582.
Topics: Amifostine; Animals; Dose-Response Relationship, Radiation; Drug Combinations; Female; Misonidazole; Nitroimidazoles; Organ Size; Parotid Gland; Radiation-Protective Agents; Rats; Time Factors; X-Rays | 1979 |
Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
Topics: Amifostine; Animals; Etanidazole; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Misonidazole; Neoplasm Metastasis; Neoplasms, Experimental; Nitroimidazoles; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1988 |
Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
Topics: Amifostine; Animals; Body Weight; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Leukocyte Count; Male; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Organothiophosphorus Compounds; Sarcoma, Experimental | 1981 |
Modification of the oral radiation death syndrome with combined WR-2721 and misonidazole.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Female; Lethal Dose 50; Mice; Mice, Inbred BALB C; Misonidazole; Mouth Mucosa; Nitroimidazoles; Organothiophosphorus Compounds; Radiation Injuries, Experimental | 1981 |
Interaction of radiosensitizers and WR-2721. I. Modification of skin radioprotection.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Female; Lethal Dose 50; Mice; Misonidazole; Nitroimidazoles; Organothiophosphorus Compounds; Oxygen; Radiation Tolerance; Skin | 1982 |
The effect of misonidazole combined with WR2721 on tumour response and leucopenia due to cyclophosphamide or melphalan.
Topics: Amifostine; Animals; Cell Survival; Cyclophosphamide; Drug Therapy, Combination; Leukopenia; Melphalan; Mice; Mice, Inbred Strains; Misonidazole; Nitroimidazoles; Organothiophosphorus Compounds; Sarcoma, Experimental | 1982 |
Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.
Topics: Amifostine; Animals; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Fibrosarcoma; Mice; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Organothiophosphorus Compounds; Radiation Tolerance; Sarcoma, Experimental | 1983 |
Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Topics: Amifostine; Animals; Cyclophosphamide; Drug Interactions; Drug Therapy, Combination; Extremities; Female; Fibrosarcoma; Lung Neoplasms; Male; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Organothiophosphorus Compounds; Time Factors | 1983 |
Radioprotection combined with hypoxic sensitization during radiotherapy of a solid murine tumor.
Topics: Amifostine; Animals; Cell Line; Dose-Response Relationship, Drug; Drug Interactions; Female; Mice; Mice, Inbred BALB C; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Organothiophosphorus Compounds; Oxygen; Radiotherapy Dosage; Statistics as Topic | 1983 |
Modification of stromal radiosensitivity by misonidazole and WR-2721.
Topics: Adenocarcinoma; Amifostine; Animals; Connective Tissue; Dose-Response Relationship, Radiation; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred CBA; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Organothiophosphorus Compounds; Radiation Tolerance | 1983 |
Time dependence of interaction of misonidazole and WR-2721.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Fibrosarcoma; Mice; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Organothiophosphorus Compounds; Sarcoma, Experimental; Time Factors | 1983 |
[Combined use of amifostine and misonidazole in experimental radiotherapy].
Topics: Amifostine; Animals; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Organothiophosphorus Compounds; Radiation-Protective Agents | 1983 |
Modification of the radiation response of the mouse kidney by misonidazole and WR-2721.
Topics: Amifostine; Animals; Dose-Response Relationship, Radiation; Female; Kidney; Mice; Mice, Inbred CBA; Misonidazole; Nitroimidazoles; Organothiophosphorus Compounds; Radiation-Protective Agents; Radiation-Sensitizing Agents; Specific Pathogen-Free Organisms | 1983 |